The results of our mutation analysis revealed upregulation of 10 targets AQP5, CDCP1, CLDN1, ERBB2, MSLN, MUC16, NECTIN4, SCNN1A, SLC44A4, and TSPAN15 in KRAS mutated pancreatic adenocarcinoma (PAAD), unlocking their potential to provide clinical benefit in this subset of patient population (Fig 5A). This evidence concerns the gene NECTIN4 and pancreatic adenocarcinoma.